✦ LIBER ✦

Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model

✍ Scribed by Simon Leung; Hideaki Miyake; Tobias Zellweger; Anthony Tolcher; Martin E. Gleave

Publisher: John Wiley and Sons
Year: 2001
Tongue: French
Weight: 111 KB
Volume: 91
Category: Article
ISSN: 0020-7136
DOI: 10.1002/1097-0215(200002)9999:9999<::aid-ijc1131>3.0.co;2-y

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Butyrate analogue, isobutyramide, inhibi

Butyrate analogue, isobutyramide, inhibits tumor growth and time to androgen-independent progression in the human prostate LNCaP tumor model

✍ Martin E. Gleave; Naohide Sato; Marianne Sadar; Virginia Yago; Nicholas Bruchovs 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 322 KB

Progression to androgen independence remains the main obstacle to improving survival and quality of life in patients with advanced prostate cancer. Induction of differentiation may serve as a rational basis for prevention of progression to androgen independence by modulating gene expression activate

Inhibition of progression to androgen-in

Inhibition of progression to androgen-independence by combined adjuvant treatment with antisense BCL-XL and antisense Bcl-2 oligonucleotides plus taxol after castration in the Shionogi tumor model

✍ Hideaki Miyake; Brett P. Monia; Martin E. Gleave 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 French ⚖ 184 KB 👁 2 views

We have reported that antisense Bcl-2 oligodeoxynucleotide (ODN) delays progression to androgen independence in the androgen-dependent (AD) mouse Shionogi tumor model. Here, we characterize changes in bcl-xL, another important anti-apoptotic gene, and test the efficacy of adjuvant antisense Bcl-xL O